News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Halsey Drug (HDGC) Announces Appointment Of Ron J. Spivey, Ph.D. As Senior Vice President And Chief Scientific Officer

10/19/2005 5:10:42 PM

PALATINE, Ill.--(BUSINESS WIRE)--April 2, 2004--Halsey Drug Co., Inc. (OTC.BB-HDGC) today announced that Ron J. Spivey, Ph.D. has been appointed Senior Vice President and Chief Scientific Officer.

Dr. Spivey has more than 25 years of pharmaceutical drug research and development experience. Most recently he served as President of Gibraltar Associates and prior to that was Vice President, Scientific Affairs for Alpharma/Purepac Pharmaceuticals. His experience encompasses all phases of the drug development process with an emphasis on formulation technology, regulatory and patent filings, R&D strategy and leadership roles. Halsey's scientific staff based in Culver, Indiana will report directly to Dr. Spivey.

Commenting, Andy Reddick, President and CEO said, "Ron has extensive experience and knowledge of all phases of pharmaceutical development and a proven track record of bringing new products to market. His leadership roles and hands on experience in developing branded and multisource products, in both large multinational companies and fast-paced entrepreneurial companies, makes him ideally suited to lead and direct our proprietary research and development programs. We are extremely pleased and excited that Ron has committed his experience and talent to help us optimize the value of Halsey's growing portfolio of innovative technology."

Dr. Spivey holds a B.A. in Zoology from Indiana University and a Ph.D. in Pharmaceutics from the University of Iowa.

Halsey Pharmaceuticals, together with its subsidiaries, is an emerging pharmaceutical technology development company specializing in proprietary drug formulation and active pharmaceutical ingredient manufacturing process development.

The statements in this press release are forward looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward looking statements involve risk and uncertainties which may affect Halsey's business prospects, including economic, competitive, governmental, technological and other factors discussed in filings with the Securities and Exchange Commission.

This and past press releases for Halsey Drug Co., Inc. are available at Halsey's web site at


Halsey Drug Co., Inc., Palatine Investor Relations Peter A. Clemens, 847-705-7709

Source: Halsey Drug Co., Inc.

Read at

comments powered by Disqus